We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+22.19%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$645M
AUM Growth
+$73.5M
Cap. Flow
-$82.4M
Cap. Flow %
-12.78%
Top 10 Hldgs %
83.04%
Holding
31
New
5
Increased
3
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.5M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.76M
3
ARRY
Array Biopharma Inc
ARRY
+$4.7M
4
TRVN
Trevena, Inc.
TRVN
+$2.75M
5
VXRT
Vaxart
VXRT
+$2.45M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$35.4M
2
CYTK icon
Cytokinetics
CYTK
+$20.5M
3
RIGL icon
Rigel Pharmaceuticals
RIGL
+$19.1M
4
XNCR icon
Xencor
XNCR
+$7.5M
5
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$3.66M

Sector Composition

Rank Sector Weight
1 Healthcare 71.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
26
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$462K 0.07%
12,500
– –
AGIO icon
27
Agios Pharmaceuticals
AGIO
$1.95B
– –
-196,996
Closed -$47K
XNCR icon
28
Xencor
XNCR
$1.59B
– –
-820,000
Closed -$7.5M
KIN
29
DELISTED
Kindred Biosciences, Inc.
KIN
– –
-51,788
Closed -$577K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2014 Portfolio in Review

As of Q1 2014, BVF Inc held 31 positions worth $645M, up 13% from $572M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

BVF Inc withdrew a net $82.4M in Q1 2014, closing 3 positions and reducing 10 holdings. Its most notable exit was Xencor, an estimated $7.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 77% a quarter earlier.

Against the trend, BVF Inc opened a new position in Trevena, Inc. worth $2.75M.

  • BVF Inc's largest Q1 2014 buy was Trevena, Inc.: 560 shares worth $2.75M.
  • BVF Inc added most to Five Prime Therapeutics, Inc. in Q1 2014, an estimated $11.5M increase.
  • BVF Inc's biggest Q1 2014 reduction was Ligand Pharmaceuticals, cutting an estimated $35.4M.
  • BVF Inc fully exited Xencor in Q1 2014, selling an estimated $7.5M.
  • BVF Inc's ten largest holdings make up 83% of its $645M portfolio in Q1 2014.
  • BVF Inc opened 5 new positions and closed 3 in Q1 2014.
  • BVF Inc's portfolio value rose 13% quarter-over-quarter to $645M.

Based on BVF Inc's 13F filing for Q1 2014, filed 15 May 2014.